# US 2001/0024829 A1 · Polyampholytes for delivering polyions to a cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024829 A1
- Document ID: US20010024829A1
- Status: Published application
- Kind: A1
- Application number: 09/753,990
- Filed: 2001-01-02
- Published: 2001-09-27
- Earliest claimed: 1997-12-30
- Assignees: MiRus LLC
- Inventors: Jon A. Wolff; James E. Hagstrom; Vladimir S. Trubetskoy; Vladimir G. Budker
- Web page: https://patentgrep.com/patent/US20010024829A1

## CPC

- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 47/58: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0008: {characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0041: {the non-active part being polymeric}
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.

## Claims

### Claim 1

A process for enhancing delivery of a polyion to a cel, comprising:
a) forming a complex of polyampholyte and polyion; and,
b) delivering the complex into a cell.

### Claim 2 (depends on 1)

The process of claim 1 wherein the polyampholyte comprises a polycation selected from group consisting of PLL and PEI.

### Claim 3 (depends on 1)

The process of claim 1 wherein the polyampholyte comprises a polyanion.

### Claim 4 (depends on 3)

The process of claim 3 wherein the polyanion comprises a molecule selected from the group consisting of succinylated PLL, succinylated PEI, polyglutamic acid, polyaspartic acid, polyacrylic acid, polymethacrylic acid, dextran sulfate, heparin, hyaluronic acid, DNA, RNA, and negatively charged proteins.

### Claim 5 (depends on 3)

The process of claim 3 wherein the polyanion comprises a molecule selected from the group consisting of pegylated derivatives, pegylated derivatives carrying specific ligands, block copolymers, graft copolymers and hydrophilic polymers.

### Claim 6 (depends on 1)

The process of claim 1 wherein the polyampholyte is delivered to a cell in vivo.

### Claim 7

A complex for delivering a polyion to a cell, comprising:
a) a polyion; and,
b) a polyampholyte wherein the polyion and the polyampholyte are bound in complex.

### Claim 8 (depends on 7)

The complex of claim 7 wherein the polyampholyte comprises a polycation.

### Claim 9 (depends on 8)

The complex of claim 8 wherein the polycation is selected from group consisting of PLL, PEI histones or cationic lipids.

### Claim 10 (depends on 7)

The complex of claim 7 wherein the polyampholyte comprises a polyanion.

### Claim 11 (depends on 10)

The complex of claim 10 wherein the polyanion comprises a molecule selected from the group consisting of succinylated PLL, succinylated PEI, polyglutamic acid, polyaspartic acid, polyacrylic acid, polymethacrylic acid, dextran sulfate, heparin, hyaluronic acid, DNA, RNA, and negatively charged proteins.

### Claim 12 (depends on 11)

The complex of claim 11 wherein the polyanion comprises a molecule selected from the group consisting of pegylated derivatives, pegylated derivatives carrying specific ligands, block copolymers, graft copolymers and hydrophilic polymers.

### Claim 13

A process for extravasation of a complex, comprising:
a) forming a complex of polyampholyte and polyion; and,
b) inserting the complex into a vessel;
c) delivering the complex to an extravascular space.

### Claim 14 (depends on 13)

The complex of claim 13 wherein the polyampholyte comprises a polycation which is selected from group consisting of PLL PEI, histones or cationic lipids.

### Claim 15 (depends on 13)

The complex of claim 13 wherein the polyampholyte comprises a polyanion selected from the group consisting of succinylated PLL, succinylated PEI, polyglutamic acid, polyaspartic acid, polyacrylic acid, polymethacrylic acid, dextran sulfate, heparin, hyaluronic acid, DNA, RNA, and negatively charged proteins.

### Claim 16 (depends on 15)

The complex of claim 15 wherein the negatively charged polyion comprises a molecule selected from the group consisting of pegylated derivatives, pegylated derivatives carrying specific ligands, block copolymers, graft copolymers and hydrophilic polymers.

### Claim 17 (depends on 13)

The process of claim 13 wherein the complex is delivered to an extravascular cell.

### Claim 18 (depends on 13)

The process of claim 13 wherein the polyion consists of a nucleic acid.

### Claim 19 (depends on 18)

The process of claim 18 wherein the nucleic acid is expressed.
